CJC-1295 (No-DAC) + Ipamorelin
Price range: $94.80 through $123.60
CJC-1295 (No-DAC) + Ipamorelin - Synergistic GH-Releasing Peptide Duo
Description
CJC-1295 (No-DAC) is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), designed to stimulate the pituitary gland to release endogenous GH without causing continuous elevation, as seen with long-acting DAC versions. Ipamorelin, on the other hand, is a selective GHRP (Growth Hormone Releasing Peptide) that acts on ghrelin receptors, amplifying GH release in a controlled, physiological pattern. When combined, these two peptides demonstrate synergistic action through dual-receptor activation — GHRH and ghrelin pathways — optimizing both amplitude and frequency of GH pulses.
This combination is extensively studied in models investigating muscle recovery, metabolic function, and cellular regeneration. In preclinical studies, the duo has been observed to enhance collagen synthesis, promote lean mass gain, and reduce adipose tissue by stimulating lipolytic pathways. The short half-life of the No-DAC variant ensures GH pulses remain physiological and transient, reducing the risk of desensitization observed with long-term continuous GH exposure.
Our formulation is provided as a stabilized pre-mixed SubQ injection pen for controlled research dosing, offering high bioavailability and ease of experimental use. This peptide duo is intended strictly for research protocols only and is not approved for human therapeutic use.
Clinical Status:
Both peptides have been evaluated in early human trials for GH deficiency and metabolic research; no regulatory approval for clinical therapy.
Evidence type:
Human RCT ✔ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory □
Mechanism of Action
CJC-1295 (No-DAC) acts by binding to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release in response to natural hypothalamic signaling. Ipamorelin binds selectively to ghrelin (GHS-R1a) receptors, triggering intracellular calcium mobilization that enhances GH pulse amplitude without significantly affecting cortisol or prolactin.
Together, these pathways synergize to produce higher and more natural GH spikes, promoting IGF-1 elevation, lipid metabolism, and tissue regeneration. This dual action creates a physiological pulsatile pattern similar to youthful GH secretion profiles.
Benefits
- Synergistic Growth Hormone Stimulation:
The combination of CJC-1295 (No-DAC) and Ipamorelin is studied for its synergistic activation of the pituitary growth hormone (GH) axis. CJC-1295 (No-DAC) enhances natural GH-releasing hormone signaling, while Ipamorelin acts as a selective ghrelin receptor agonist. Together, they amplify pulsatile GH secretion, leading to increased IGF-1 levels and broad systemic support for tissue repair, recovery, and metabolism in research models. - Enhanced Muscle Growth and Recovery:
This peptide pairing has been observed to support lean muscle development through improved nitrogen retention, protein synthesis, and satellite cell activation. The GH-IGF-1 cascade activated by this combination enhances muscle fiber repair and post-exercise recovery, making it highly relevant in regenerative and performance-related studies. - Improved Sleep and Cellular Regeneration:
Research shows that CJC-1295 + Ipamorelin enhances deep sleep quality by increasing natural GH pulses during the night. These nocturnal GH peaks are associated with accelerated cellular repair, collagen production, and improved recovery capacity — all critical factors for tissue restoration and long-term metabolic health. - Reduction of Adipose Tissue and Fat Oxidation:
Through its influence on growth hormone signaling, this peptide combination stimulates lipolysis and fatty acid mobilization while inhibiting lipogenesis. This metabolic rebalancing supports reduced body fat levels and improved body composition without altering appetite or blood glucose, highlighting its value in body recomposition and metabolic optimization research. - Increased Collagen Production and Skin Quality:
The GH-IGF-1 axis stimulated by CJC-1295 + Ipamorelin promotes collagen synthesis and skin elasticity. Studies suggest improved dermal thickness and hydration, positioning this combination as a promising model for research into anti-aging and regenerative dermatology. - Support for Bone Density and Joint Integrity:
Growth hormone pulses initiated by this combination stimulate osteoblastic activity and calcium retention, improving bone mineral density and supporting joint health. The resulting enhancement of connective tissue integrity makes it a key focus in musculoskeletal regeneration and aging-related bone metabolism research. - Improved Energy, Mood, and Cognitive Function:
By modulating GH and IGF-1 signaling, this combination has been observed to improve mental clarity, focus, and overall well-being. The enhanced mitochondrial energy production associated with GH stimulation contributes to better vitality, motivation, and cognitive performance under metabolic stress conditions. - Restoration of Hormonal Rhythm and Homeostasis:
CJC-1295 (No-DAC) + Ipamorelin is studied for its ability to restore natural GH pulsatility that typically declines with age. This restoration supports circadian alignment, balanced endocrine output, and rejuvenated cellular function, providing a physiological approach to age-related hormonal decline models. - Enhanced Recovery from Injury and Physical Stress:
Through its regenerative effects on muscle, tendon, and joint tissues, this combination enhances healing and recovery rates following physical strain or injury. The GH-mediated increase in collagen formation, cellular proliferation, and angiogenesis contributes to faster restoration of function in experimental recovery settings. - Improved Metabolic Efficiency and Body Composition:
Studies indicate that GH secretagogues like CJC-1295 and Ipamorelin enhance basal metabolic rate and nutrient utilization. This effect supports improved fat-to-muscle ratio, increased energy levels, and more efficient metabolic activity, making it a promising subject in obesity, longevity, and metabolic optimization research. - Synergistic Longevity and Anti-Aging Potential:
By sustaining GH-IGF-1 signaling and improving mitochondrial function, this combination supports cellular rejuvenation and longevity pathways. When combined with peptides such as MOTS-c, SS-31, or NAD+, it offers a comprehensive research model for studying anti-aging mechanisms, mitochondrial protection, and energy system preservation.
Research Data
| Study/model | Reported effect |
| Rat pituitary cell assays |
↑ GH release via GHRH receptor stimulation (CJC-1295 No-DAC)
|
| Human GH-deficiency pilot (CJC-1295 + Ipamorelin) |
↑ serum GH and IGF-1 levels with maintained circadian rhythm
|
| Preclinical metabolic models |
↓ fat mass and ↑ lean tissue via GH-mediated lipolysis
|
| Aged rodent models |
Improved collagen synthesis and muscle fiber repair
|
| Comparative GHRP studies |
Ipamorelin showed minimal cortisol elevation vs GHRP-6
|
| In vitro somatotroph analysis |
Dual receptor activation → enhanced GH pulse amplitude
|
Stack Suggestions
CJC-1295 (No-DAC) + Ipamorelin is often combined with:
- GHK-Cu → Supports skin and connective tissue regeneration
- BPC-157 + TB-500 → Complements recovery and tissue healing
- NAD+ → Enhances mitochondrial energy metabolism and cellular recovery
- MOTS-c → Synergizes in metabolic optimization protocols
Stacks discussed are for experimental design; not safety/efficacy guidance.
Pen Dosage Chart
| CJC 1295 (No DAC) + Ipamorelin Pen 5 + 5 mg | |
| Volume | 2.0 mL |
| mg/mL | 1 mg/mL |
| Click-to-Dose | 1 click = 0.10 mg |
| Example(s) | 10 clicks = 10 mg |
| CJC 1295 (No DAC) + Ipamorelin Pen 5 + 10 mg | |
| Volume | 2.0 mL |
| mg/mL | 1.5 mg/mL |
| Click-to-Dose | 1 click = 0.15 mg |
| Example(s) | 10 clicks = 15 mg |
Dosage & Protocols Variations
Standard Research Protocol
- Dose: 0.25 + 0.5 mg
- Duration: 8 – 12 weeks
- Frequency: 1× daily
- Cycle Interval: 4-week rest
- Goal / Description: Baseline GH and IGF-1 enhancement in research models
Performance Study Protocol
- Dose: 0.5 + 1.0 mg
- Duration: 8 – 12 weeks
- Frequency: 1× daily (evening)
- Cycle Interval: 8-week rest
- Goal / Description: Designed for muscle recovery and metabolic modulation experiments
Every Other Day Protocol
- Dose: 0.5 + 0.5 mg
- Duration: 8 – 12 weeks
- Frequency: Every Other Day
- Cycle Interval: 4-week rest
- Goal / Description: Pulsatile GH release pattern; minimizes receptor desensitization
Extended Regeneration Protocol
- Dose: 0.5 + 0.5 mg
- Duration: 12 – 16 weeks
- Frequency: 1× daily
- Cycle Interval: 8-week rest
- Goal / Description: Long-term tissue recovery, collagen stimulation, and fat metabolism support
Possible Side Effects
CJC-1295 (No-DAC) and Ipamorelin are generally observed to be well-tolerated in research, particularly Ipamorelin due to its selectivity in not raising cortisol or prolactin levels. However, as with all peptides, a range of possible side effects may be observed, particularly in the initial stages of administration or with higher doses.
Injection Site Reactions: The most common adverse reactions are typically localized to the administration site. These may include mild pain, redness, irritation, or swelling immediately following the subcutaneous injection. These reactions are usually transient and often decrease with continued administration. Proper rotation of injection sites is a key guideline to minimize this occurrence.
Water Retention (Edema): Increased Growth Hormone (GH) levels can sometimes lead to the body holding onto extra fluid, which may result in temporary bloating or mild swelling in the extremities. This effect is manageable but may be more pronounced in initial weeks.
Headaches or Flushing: Some subjects report mild to moderate headaches, which may be related to fluctuations in GH and blood flow. A warm sensation or flushing of the face and neck is also a reported side effect, often occurring shortly after injection and subsiding within minutes.
Tingling or Numbness (Paresthesia): Changes in GH and IGF-1 can occasionally lead to a sensation of tingling, often in the hands or feet. This symptom is typically mild and is a known effect associated with GH elevation.
Dizziness or Hyperactivity: Less than 1 percent of patients report dizziness or a feeling of mild hyperactivity shortly after administration.
It is important to emphasize that most observed side effects are temporary and mild. Research protocols must include careful monitoring and adherence to recommended dosage to ensure safety and manage any adverse reactions.
Product Attributes
- CAS #: CJC-1295 (No-DAC) – 863288-34-0; Ipamorelin – 170851-70-4
- Molecular Formula: CJC-1295 (No-DAC) – C152H252N44O42; Ipamorelin – C38H49N9O5
- Sequence (AA): CJC-1295 (No-DAC) – Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Gln-Ala-His-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Gln-Ala-His-Asn-Ser-Tyr-Arg-Lys-Leu-Leu; Ipamorelin – Aib-His-D-2-Nal-D-Phe-Lys-NH₂
- Molecular Weight: ~3367.9 g/mol (CJC-1295 No-DAC), 711.9 g/mol (Ipamorelin)
- PubChem CID: CJC-1295 (No-DAC) – 91976842; Ipamorelin – 9831659
- Half-Life: CJC-1295 (No-DAC) ~30 min; Ipamorelin ~2 hr
- Synonyms: Mod/Modified GRF (1-29), GHRH analog, GHRP-Ipamorelin, NNC-26-0161, IPAMORELIN ACETATE
- Type: Synthetic Analog (GHRH Analog) + Synthetic Peptide (GHRP)
- Research Focus: Recovery & Performance, Metabolism, Anti-Aging
Scientific References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Human RCT
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GHRH analog Human RCT
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects Human RCT
- CJC-1295 + Ipamorelin: synergy and pharmacodynamic modelling overview Animal & In vitro
- Beyond the androgen receptor: the role of growth hormone secretagogues including ipamorelin Review
- CJC-1295 Safety profile: Subcutaneous administration in phase 1 trials Human RCT
- Identification of CJC-1295, a growth-hormone-releasing peptide, in antidoping analyses In vitro
- High sensitivity mass spectrometric quantification of serum growth hormone: implications for GHRH analogs In vitro
- Ipamorelin: selective agonist of the ghrelin/GHS-R-1a receptor and growth hormone secretagogue Review
- CJC-1295 + Ipamorelin combination – FDA regulatory document Regulatory
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™ – precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1 – 7°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6 – 8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS cold-chain transport boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not support merchants in this field.
For this reason, we accept bank transfers only.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day (cut-off dependent).
This method ensures compliance, security, and continuity of service for all customers across the EU.
